Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224986 | 0.93 | NR1H2 (0.74) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL19456156 | 0.93 | NR1H2 (0.74) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL10242790 | 0.93 | NR1H2 (0.74) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL25010845 | 0.93 | NR1H2 (0.74) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL23453545 | 0.89 | JAK2 (0.54) | NR1H2JAK1JAK2HPGDHDAC1 | |
| SCHEMBL16348045 | 0.86 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2HPGDUSP30 | |
| SCHEMBL24718098 | 0.84 | NR1H2 (0.63) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL24990169 | 0.84 | NR1H2 (0.63) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL24740662 | 0.84 | NR1H2 (0.68) | NR1H2USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL21561564 | 0.84 | NR1H2 (0.63) | NR1H2USP2SMN1; SMN2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-07 | — | — | US | disclosed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-30 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11708359-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-25 | — | — | US | disclosed |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-20 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-19 | — | — | US | disclosed |
| WO-2021113479-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253565-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | NR1H2 137/4885USP2 861/4885SMN1; SMN2 3461/4885 |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | NR1H2 2413/4885USP2 3620/4885SMN1; SMN2 4438/4885 |
| US-11974987-B2 | Monoacylglycerol lipase modulators for use in autism spectrum disorders | LIPC, LPL, MGLL | NR1H2 343/4885USP2 314/4885SMN1; SMN2 2081/4885 |
| US-11708359-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, LIPC | NR1H2 137/4885USP2 861/4885SMN1; SMN2 3461/4885 |
| US-20230117611-A1 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | LIPC, LPL, MGLL | NR1H2 343/4885USP2 314/4885SMN1; SMN2 2081/4885 |
| US-20230382902-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, LIPC | NR1H2 137/4885USP2 861/4885SMN1; SMN2 3461/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | NR1H2 134/4885USP2 3363/4885SMN1; SMN2 375/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | NR1H2 205/4885USP2 2941/4885SMN1; SMN2 432/4885 |
| US-20210171535-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | NR1H2 2413/4885USP2 3620/4885SMN1; SMN2 4438/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | NR1H2 205/4885USP2 2941/4885SMN1; SMN2 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.